Specialty Pharmacy

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.

Top news of the day from across the health care landscape.

Ramucirumab (Cyramza, Eli Lilly) is approved as a single agent in patients with elevated alpha fetoprotein who have been previously treated with sorafenib.

The pathway is intended to help patients by making more treatment options available through biosimilar and interchangeable products.

This product is a generic version of Genentech's Tarceva.

Compared with interferon beta-1a, ozanimod reduced less cortical grey matter volume in patients with relapsing forms of multiple sclerosis.

An investigational therapy for amyotrophic lateral sclerosis has shown promise in slowing the progression of the disease in patients with a genetic form of the disease.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Study finds the number of patients who are eligible for and may respond to checkpoint inhibitor therapies is higher than for genome-driven therapies.

Eighty-three percent of physicians excising more-than-necessary amounts of tissue on a regular basis during Mohs micrographic surgery.

Top news of the day from across the health care landscape.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discusses some of the ways that Walgreens is advancing care for patients with cancer.

Premier Inc. announced on Tuesday it is selling its specialty pharmacy business to ProCare Pharmacy LLC, a subsidiary of CVS Health Corporation.

There is no cure for multiple sclerosis, but there are more than a dozen treatment options that aid in reducing the severity of the disease.

Treatment with tagraxofusp yielded high response rates in patients with blastic plasmacytoid dendritic cell neoplasm.

Top news of the day from across the health care landscape.

Using genetic testing for women newly diagnosed with breast cancer can decrease the high cost of chemotherapy use in the first year of care.

Top news of the day from across the health care landscape.

Amifampridine (Ruzurgi, Jacobus) is the first treatment approved specifically for pediatric patients 6 to 17 years of age with Lambert-Eaton myasthenic syndrome.

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma.

Ado-trastuzumab emtansine (Kadcyla) is currently the only antibody-drug conjugate approved for the treatment of HER2-positive early and metastatic breast cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, talks about the growing role of specialty pharmacies in delivering cancer care.

Top news of the day from across the health care landscape.

Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.

Officials with the FDA have approved AstraZeneca’s dapagliflozin, saxagliptin and metformin hydrochloride (Qternmet XR) extended release tablets for adults with type 2 diabetes.

A molecular switch in the skin cells may cause increased susceptibility to autoimmunity in women.

It was during the middle of the night when Suzanne Soliman, PharmD, founder of the Pharmacist Mom Group on Facebook, got the idea for her group page, which has since grown to be one of the most active on the popular social media platform, with more than 2 million posts last year alone.

At the Asembia Specialty Pharmacy Summit 2019, Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discussed top trends in specialty pharmacy that are likely to continue to impact the industry.